Revised Recommendation of Aspirin to be used as Primary Prevention of Cardiovascular Disease

The use of aspirin for primary prevention of cardiovascular disease (CVD) has been debated in recent years. According to the U.S. Preventive Services Task Force (USPSTF), aspirin may provide a small net benefit for adults aged 40 to 59 years with a 10% or greater 10-year CVD risk, but the decision should be individualized. However, for adults 60 years or older, the USPSTF recommends against initiating aspirin for primary prevention due to the increased risk of bleeding complications.

Key Considerations

• Potential Benefits: Aspirin may reduce the risk of nonfatal heart attacks and strokes in individuals at higher CVD risk.
• Risks: Increased likelihood of gastrointestinal bleeding, intracranial bleeding, and hemorrhagic stroke, especially in older adults.
• Guideline Updates: The USPSTF no longer recommends routine aspirin use for primary prevention in adults over 60.
• Secondary Prevention: Aspirin remains recommended for individuals with a history of heart attack, stroke, or cardiovascular procedures

Revised recommendations for aspirin use, particularly for the primary prevention of cardiovascular disease (CVD), have shifted to a more individualized approach based on age, calculated CVD risk, and bleeding risk. Here’s an overview of the updated guidance:

Key Points of the Revised Recommendations

Primary Prevention in Adults Without Known CVD:

1. Ages 40 to 59 Years:
   • Risk-Based Decision Making: For adults in this age group who have an estimated 10-year CVD risk of 10% or greater, initiating low‑dose aspirin should be considered on an individual basis.
   • Shared Decision-Making: The decision to start aspirin is not a blanket recommendation; instead, it should be reached collaboratively between the patient and the healthcare provider. This discussion should weigh the relatively small net benefit of aspirin against the potential risk of bleeding.
   • Grade of Recommendation: This approach has been assigned a moderate recommendation level (Grade C), reflecting that while some benefit is expected, the balance of risks and benefits varies by individual.
2. Age 60 Years and Older:
   • Not Recommended for Primary Prevention: For adults in this age range, the evidence indicates that the potential harms of low-dose aspirin (especially bleeding complications) tend to outweigh the benefits. Consequently, the recommendation is against initiating aspirin therapy for CVD primary prevention in this group (Grade D).

2.Secondary Prevention:

Continued Use in Established CVD:

• For individuals with a history of heart attack, stroke, or a history of vascular interventions (such as stenting), aspirin remains an important part of treatment for secondary prevention. The revised recommendations do not apply to these patients. They should continue their low-dose aspirin regimen as directed by their healthcare provider.

Why These Changes Matter

• Tailoring Therapy: The updated guidance reflects a growing emphasis on personalization in preventive care. Rather than applying a “one size fits all” method, the recommendations now stress evaluating each patient’s overall risk profile—including both their likelihood of cardiovascular events and their risk for bleeding events—before starting aspirin.
• Evolving Evidence: Recent studies have shown that the absolute benefit of low-dose aspirin in reducing heart attacks and strokes in primary prevention is relatively modest, particularly in an era of improved risk factor control (for example, better cholesterol management and blood pressure control). In contrast, the risk of bleeding (especially gastrointestinal or intracranial bleeding) increases with age.
• Preventive Balance: These changes underscore the principle that a preventive medication like aspirin—although time-tested and effective in certain populations—must be used judiciously. For younger individuals with higher CVD risk and low bleeding risk, the benefits might justify its use. For older adults or those with higher bleeding risk, the potential adverse effects tip the balance against routine use.

Implications for Nursing and Clinical Practice

• When counseling patients about preventive strategies, healthcare providers (including nurses) play a crucial role in:
  • Risk Assessment: Educating patients on their estimated cardiovascular risk and factors that might predispose them to bleeding.
  • Individualizing Care: Facilitating shared decision-making conversations that incorporate the patient’s preferences, risk factors, and values.
  • Ongoing Monitoring: Maintaining engagement with patients who are on aspirin therapy for continued evaluation of benefits versus risks over time.

The updated USPSTF recommendations, which replace the previous USPSTF 2016 statement, generally aligns with the guidance from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease that states aspirin should be used infrequently in the routine primary prevention of ASCVD.

Specifically, the ACC/American Heart Association primary prevention guideline recommends:

• Low-dose aspirin (75-100 mg orally daily) might be considered for the primary prevention of ASCVD among select adults 40 to 70 years of age who are at higher risk ASCVD risk but not at increased bleeding risk (class of recommendation [COR] IIb, level of evidence [LOE] A).
• Low-dose aspirin 75-100 mg orally daily) should not be administered on a routine basis for the primary prevention of ASCVD among adults >70 years of age (COR III [harm], LOEB-R).
• Low-dose aspirin 75-100 mg orally daily) should not be administered for the primary prevention of ASCVD among adults of any age who are at increased risk of bleeding (COR III [harm], LOE C-LD).

REFERENCES

1. US Preventive Services Task Force, Davidson KW, Barry MJ, et alAspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA 2022; 327(16): 1577–1584. doi:10.1001/jama.2022.4983
2. Bibbins-Domingo K; US Preventive Services Task Force.Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2016; 164(12):836–845. doi:10.7326/M16-0577
3. Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596–e646. https://doi.org/10.1161/CIR.0000000000000678
4. Ittaman, S. V., VanWormer, J. J., & Rezkalla, S. H. (2014). The role of aspirin in the prevention of cardiovascular disease. Clinical medicine & research, 12(3-4), 147–154. https://doi.org/10.3121/cmr.2013.1197

Stories are the threads that bind us; through them, we understand each other, grow, and heal.

JOHN NOORD

Connect with “Nurses Lab Editorial Team”

I hope you found this information helpful. Do you have any questions or comments? Kindly write in comments section. Subscribe the Blog with your email so you can stay updated on upcoming events and the latest articles.